Myasthenia gravis: a changing pattern of incidence

I Casetta1, E Groppo, R De Gennaro

  • 1Section of Clinical Neurology, Department of Medical and Surgical Sciences of Communication and Behavior, Neuroscience Center, University of Ferrara, Corso della Giovecca 203, 44100, Ferrara, Italy. cti@unife.it

Journal of Neurology
|July 13, 2010
PubMed

Insights

Myasthenia gravis (MG) incidence shows a shift towards later onset, with increasing late-onset cases and decreasing early-onset cases. This epidemiological change in MG may be influenced by unidentified environmental factors.

Area of Science:

  • Neurology
  • Epidemiology

Background:

  • Myasthenia gravis (MG) incidence has been reported to be increasing since the mid-1980s, primarily due to late-onset cases.
  • The reasons for this increase, whether population aging, improved diagnostics, or a true rise in incidence, remain debated.

Purpose of the Study:

  • To estimate the incidence and temporal trends of myasthenia gravis (MG) in the province of Ferrara, Italy, from 1985 to 2007.
  • To investigate changes in the age of onset for MG over time.

Main Methods:

  • A complete enumeration approach was employed, reviewing all case sources in Ferrara, Italy.
  • Age-adjusted incidence rates were calculated and analyzed for temporal trends.
  • Incidence rates for early-onset and late-onset MG were compared over different periods.

Main Results:

  • The mean annual age-adjusted MG incidence was 18 per 1,000,000, with no overall significant temporal trend.
  • While early-onset MG incidence decreased (p < 0.01), late-onset MG incidence significantly increased (p < 0.05) after 1990.
  • The median age at disease onset steadily increased over the study period, particularly for nonthymoma MG.

Conclusions:

  • A significant shift in MG epidemiology towards later onset has occurred, characterized by an increasing frequency of late-onset MG and a decreasing frequency of early-onset MG.
  • This changing pattern suggests potential influence from unknown environmental factors impacting MG epidemiology.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...